Stachyose
(Synonyms: 水苏糖) 目录号 : GC18245
Stachyose是一种寡糖，也是一种益生元。
Cas No.:470-55-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Stachyose is an oligosaccharide and prebiotic[1]. Stachyose also serves as a specific inhibitor of PRDX5 (peroxiredoxin 5), acts directly on the PRDX5 protein, and inhibits its enzymatic activity[2]. Stachyose is commonly used in research on castration-resistant prostate cancer and metabolic diseases such as type 2 diabetes[3][4].
In vitro, Stachyose (0.4-3.2mg/mL in medium; 24h) dose-dependently inhibited Caco-2 colon cancer cells proliferation, induced cells apoptosis, decreased mitochondrial membrane potential, upregulated Bax, downregulated Bcl-2, promoted cytochrome C release, and activated caspases 3/9[5].
In vivo, Stachyose (200-600mg/kg/day; oral gavage for 3 weeks) dose-dependently alleviated DSS-induced colitis symptoms, increased tight junction protein expression (Occludin, Claudin-1, ZO-1), decreased pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), increased anti-inflammatory cytokine IL-10, and restored Treg/Th17 cell balance in a DSS-induced colitis mouse model[6]. Stachyose (1 or 5g/kg/day; oral gavage for 3 days) reduced myocardial infarction area and improved cardiac function in a mouse model of myocardial ischemia-reperfusion injury[7].
References:
[1] Li CN, Wang X, Lei L, et al. Berberine combined with stachyose induces better glycometabolism than berberine alone through modulating gut microbiota and fecal metabolomics in diabetic mice. Phytother Res. 2020;34(5):1166-1174.
[2] Wang R, Pan Y, Zhang L, et al. Prebiotic stachyose inhibits PRDX5 activity and castration-resistant prostate cancer development. Int J Biol Macromol. 2024;278(Pt 3):134844.
[3] Wang R, Mi Y, Ni J, et al. Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer. Adv Sci (Weinh). 2024;11(9):e2304939.
[4] Wu Y, Cao Y, Feng L, et al. The natural compound stachyose targets SGLT2-mediated metabolic reprogramming to ameliorate diabetic kidney disease. Phytomedicine. 2025;147:157182.
[5] Huang G, Mao J, Ji Z, Ailati A. Stachyose-induced apoptosis of Caco-2 cells via the caspase-dependent mitochondrial pathway. Food Funct. 2015;6(3):765-771.
[6] He N, Chen K, Yu S, et al. Stachyose Exerts Anticolitis Efficacy by Re-balancing Treg/Th17 and Activating the Butyrate-Derived PPARγ Signaling Pathway. J Agric Food Chem. 2024;72(21):12171-12183.
[7] Zhang AY, Su JB, Sun HT, et al. Stachyose ameliorates myocardial ischemia-reperfusion injury by inhibiting cardiomyocyte ferroptosis and macrophage pyroptosis. Int Immunopharmacol. 2024;143(Pt 1):113334.
Stachyose是一种寡糖，也是一种益生元[1]。Stachyose还作为PRDX5（过氧化物还原酶5）的特异性抑制剂，直接作用于PRDX5蛋白并抑制其酶活性[2]。Stachyose常用于去势抵抗性前列腺癌和2型糖尿病等代谢性疾病的研究[3][4]。
体外实验中，Stachyose（0.4-3.2mg/mL in medium；24小时）剂量依赖性地抑制了Caco-2结肠癌细胞的增殖，诱导细胞凋亡，降低了线粒体膜电位，上调了Bax蛋白，下调了Bcl-2蛋白，促进了细胞色素C的释放，并激活了caspase 3/9[5]。
体内实验中，在DSS诱导的结肠炎小鼠模型中，Stachyose（200-600 mg/kg/天；口服给药3周）剂量依赖性地减轻了DSS诱导的结肠炎症状，增加了紧密连接蛋白（Occludin、Claudin-1、ZO-1）的表达，降低了促炎细胞因子（TNF-α、IL-1β、IL-6）的水平，增加了抗炎细胞因子IL-10的水平，并恢复了Treg/Th17细胞的平衡[6]。Stachyose（1或5g/kg/天；口服给药3天）减少了心肌缺血再灌注损伤小鼠的心肌梗死面积，改善了小鼠的心脏功能[7]。
| Cell experiment [1]: | |
Cell lines | Caco-2 cells |
Preparation Method | Caco-2 cells from passages 30 to 50 were used in this experiment. After reaching subconfluence, Caco-2 cells were recovered from the culture flask through 0.25% trypsin digestion after washing twice with PBS. The medium was changed every 2d. Cell counts based on conductivity measurements and cell viability were assessed using the trypan blue test. To evaluate the cytotoxic effect of Stachyose, cells in the log phase were seeded in 96-well cell culture plates (104 cells per well) and pre-incubated for 24h. The cells were then treated with Serum free medium (SFM) mixed with different Stachyose concentrations (0, 0.4, 0.8, 1.6, 3.2mg/mL) for 24h. The MTT assay was used to measure cell viability according to the commercially available protocol. Flow cytometry analysis for cell apoptosis was performed by using an annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) apoptosis detection kit. |
Reaction Conditions | 0.4-3.2mg/mL; 24h |
Applications | Stachyose dose-dependently inhibited Caco-2 colon cancer cells proliferation and induced cells apoptosis. |
| Animal experiment [2]: | |
Animal models | Male C57BL/6J mice |
Preparation Method | Male C57BL/6J mice, aged 6 weeks were housed in a controlled environment with regulated humidity and temperature, and were provided free access to standard chow and clean water on a 12-h light-dark cycle. After one week acclimatization, the effects of Stachyose on a mouse model of MIRI were evaluated. Stachyose (1 or 5g/kg/day) was administered via gavage for three consecutive days before sham or MIRI surgery. The MIRI model was established under clean and standardized conditions. Echocardiography was performed using the Vevo 3100LT ultrasound cardiography system. After the echocardiography was completed, the mice were euthanized by cervical dislocation, the chest skin and ribs were incised, and the apex of the heart was rinsed with physiological saline. The hearts were then removed and frozen at -20℃ for 20min. Once the hearts were fully frozen, it was dissected using a surgical tool. The hearts were then soaked in 2,3,5-triphenyltetrazolium chloride (TTC dye) at 37℃ for 30min. The necrotic area appeared white, while the viable myocardium was red. After being incubated in 4% paraformaldehyde for 24h, the heart was photographed against a white background. |
Dosage form | 1 or 5g/kg/day; oral gavage for 3 days |
Applications | Stachyose reduced myocardial infarction area and improved cardiac function in a mouse model of myocardial ischemia-reperfusion injury. |
References: | |
| Cas No. | 470-55-3 | SDF | |
| 别名 | 水苏糖 | ||
| 分子式 | C24H42O21 | 分子量 | 666.58 |
| 溶解度 | H2O : 125 mg/mL (Need ultrasonic) | 储存条件 | Store at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5002 mL | 7.501 mL | 15.002 mL |
| 5 mM | 300 μL | 1.5002 mL | 3.0004 mL |
| 10 mM | 150 μL | 750.1 μL | 1.5002 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >80.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet